FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
{{output}}
Background: More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin (IL)-23 receptor signaling, versus placebo at Week(W)16 of the phase 2 FRONTI... ...
